LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands. Show more

Location: Yalelaan 62, Utrecht, 3584 CM, Netherlands | Website: https://www.lavatherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

35.78M

52 Wk Range

$0.85 - $2.39

Previous Close

$1.35

Open

$1.36

Volume

13,995

Day Range

$1.34 - $1.38

Enterprise Value

-31.52M

Cash

66.56M

Avg Qtr Burn

-7.587M

Insider Ownership

32.69%

Institutional Own.

36.96%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.